

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III PHEREXA trial evaluating trastuzumab/capecitabine with or without pertuzumab after disease progression on trastuzumab-based therapy for HER2-positive mBC met its primary endpoint of progression-free survival.
  - True
  - False
- The Phase III HERITAGE trial comparing the trastuzumab biosimilar Myl-14010 to trastuzumab for patients with HER2-positive mBC demonstrated \_\_\_\_\_ efficacy with Myl-14010.
  - Greater
  - Lesser
  - Equivalent
- Results presented at ASCO 2016 by Adams and colleagues evaluating atezolizumab in combination with *nab* paclitaxel for patients with mTNBC indicated that the combination is tolerable with promising activity.
  - True
  - False
- The anti-PD-1 agent pembrolizumab and the anti-PD-L1 agent atezolizumab typically produce response rates of approximately \_\_\_\_\_ for patients with mTNBC.
  - 18% to 20%
  - 35% to 40%
  - 60% to 70%
- Results reported at ASCO 2016 by Rugo and colleagues from the Phase II SWISH trial demonstrated that prophylactic use of an oral dexamethasone solution markedly decreased the incidence and severity of stomatitis in patients receiving everolimus/exemestane for ER-positive mBC.
  - True
  - False
- The Phase III EMBRACA trial is evaluating \_\_\_\_\_ for patients with BRCA mutation-positive locally advanced or metastatic BC.
  - Niraparib
  - Olaparib
  - Talazoparib
  - Veliparib
- The Phase III MA17R trial evaluating the extension of adjuvant letrozole for 5 years after an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen for early-stage BC demonstrated no improvement in outcomes with the extended duration of aromatase inhibitor therapy.
  - True
  - False
- Data presented at ASCO 2016 from the Phase III PALOMA-2 trial evaluating palbociclib with letrozole versus letrozole alone for patients with ER-positive, HER2-negative advanced BC who had not received prior systemic therapy for their advanced disease \_\_\_\_\_ the significant clinical benefit and safety of this combination previously reported by the Phase II PALOMA-1 trial.
  - Confirmed
  - Failed to confirm
- Single-agent activity has been reported with which of the following CDK4/6 inhibitors in patients with ER-positive, HER2-negative mBC?
  - Abemaciclib
  - Palbociclib
  - Ribociclib
  - None of the above
- Which of the following strategies is being evaluated in the Phase II MonarchER trial?
  - Concurrent targeting of the HER2 and hormonal pathways
  - Addition of a CDK4/6 inhibitor to anti-HER2 therapy
  - Both a and b